Home/ Stocks/ BOLT

Bolt Biotherapeutics, Inc. Common Stock

BOLT XNAS

$4.05 +0.18 (+4.65%) ▲ 15-min delayed

Open

$4.15

High

$4.15

Low

$3.87

Volume

14.0K

Market Cap

$7.44M

About Bolt Biotherapeutics, Inc. Common Stock

Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 23 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$26.0K	$-7,244,000	$-4.31
FY 2025	$7.70M	$-33,376,000	$-17.85
Q3 2025	$2.17M	$-7,144,000	$-3.72
Q2 2025	$1.80M	$-8,561,000	$-4.46

Related Market News

No specific coverage for BOLT yet. Check out our latest market news or earnings calendar.

Get BOLT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Bolt Biotherapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.